Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Christopher S Anderson · UNIVERSITY OF ROCHESTER · 2024 · $101,672 — Respiratory Syncytial Virus (RSV) is the second leading cause of hospitalization in children worldwide and has been increasing appreciated as a cause of hospitalization and death in the elderly. Recent studies have shown that polyvalent vaccine formulations, mixture of antigens derived from distinct…
Gaurav Sahay · OREGON STATE UNIVERSITY · 2024 · $530,230 — PROJECT ABSTRACT RNA therapeutics and their corresponding nanomedicines are poised to rapidly change the landscape of healthcare. To address needs in various diseases, RNA-based technologies must function in vivo with biological interactions at various levels from whole body (systemic biodistributio…
Jie Sun · UNIVERSITY OF VIRGINIA · 2024 · $697,498 — PROJECT SUMMARY/ABSTRACT In the wake of a global pandemic caused by the ancestral strain of SARS-CoV-2, infections with emerging variant strains are an ongoing cause of morbidity and mortality. Robust respiratory mucosal immune responses to SARS-CoV-2 infection and/or vaccination are vital to preven…
qing sun · TEXAS ENGINEERING EXPERIMENT STATION · 2024 · $359,373 — Among all approaches, messenger RNA (mRNA)-based vaccines have emerged as a rapid and versatile candidate to quickly respond to virus pandemics, including coronavirus disease 2019 (COVID-19). But mRNA vaccines face key potential limitations. Researchers have observed that RNA molecules tend to spont…
Michela Locci · UNIVERSITY OF PENNSYLVANIA · 2024 · $668,622 — SUMMARY Messenger RNA (mRNA) vaccines represent a powerful vaccine approach for the induction of protective immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since this vaccine platform was approved for human use in 2020 for the first time, little is known about …
Milka Koupenova · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $418,750 — PROJECT SUMMARY Influenza infection increases the incidence of acute MI (AMI) within the first 7 days after detection and the therapeutic benefit of vaccination is comparable to current therapies for secondary prevention of AMI. Platelets are the blood component central to thrombosis and uncontroll…
Hao Cheng · DREXEL UNIVERSITY · 2024 · $318,457 — Project Summary Biologic drugs and nanomedicines with conjugated polyethylene glycol (PEG) show extended circulation in the blood, increasing therapeutic efficacy. The U.S. FDA has approved more than 30 PEGylated biologics, including proteins, nucleotides, and peptides, and a few PEGylated nanomedi…
Zhengjie Zhou · UNIVERSITY OF CHICAGO · 2024 · $110,623 — Project Summary/Abstract: This proposal describes a research and career development plan for Zhengjie Zhou, Ph.D., to transit from a postdoctoral fellow to an independent investigator position. This proposal will be based on Dr. Zhou’s past years of multidisciplinary research in nanomedicine and vas…
Robbie B Mailliard · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $739,018 — ABSTRACT The CDC recommends that persons living with HIV (PWH) be vaccinated against SARS-CoV-2. However, there are minimal scientific data to support this important public health principle in relation to ongoing immune dysfunction and chronic comorbidities and the persistent HIV reservoir in antire…
Rajesh Thippeshappa · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2024 · $99,000 — Abstract/Summary: Commonly used animal models of HIV-1 include infection of macaques with Simian Immunodeficiency Virus (SIV) or Simian-Human Immunodeficiency Virus (SHIV) containing HIV envelope (Env) or reverse transcriptase. These animal models have been extremely useful in understanding HIV path…
Yoann Aldon · FRED HUTCHINSON CANCER CENTER · 2024 · $832,117 — PROJECT SUMMARY/ABSTRACT This research proposal aims to develop new immunogens for an HIV-1 vaccine by utilizing advanced protein design techniques and deep learning methods. Conventional structure-guided approaches have limitations in achieving desired structural characteristics. Therefore, this st…
Jalene Velazquez · WASHINGTON STATE UNIVERSITY · 2024 · $45,214 — PROJECT SUMMARY Survivors of Ebola virus disease (EVD) have reported a wide range of symptoms following recovery from infection. These long-term sequelae are severe enough to interfere with their daily lives and are now collectively referred to as post-Ebola syndrome (PES). Although post-viral sympt…
MICHAEL ANDREW FISCHBACH · STANFORD UNIVERSITY · 2024 · $751,181 — PROJECT SUMMARY/ABSTRACT Eliciting or suppressing an adaptive immune response has become central to oncology, autoimmunity, and infectious disease. Checkpoint inhibitors have revolutionized the treatment of cancer, while TNF inhibitors and other immune-suppressive biologics have become the standard …
Gordon Parry · AMPEDRNA BIOSCIENCES LLC · 2024 · $398,823 — Human papillomavirus (HPV) is responsible for a large proportion of global cancer cases, including head and neck, cervical and anal cancers, among others. HPV-related cancers are caused by certain high-risk strains of the virus, which can cause long-lasting infections that eventually lead to the dev…
Peter Palese · ROCKEFELLER UNIVERSITY · 2024 · $862,508 — ABSTRACT Licensed influenza vaccines commonly elicit strain-specific immunity, failing to provide protection against antigenically distinct strains with the capacity to cause pandemic outbreaks. Therefore, the development of a universal influenza vaccine with the capacity to elicit lifelong protecti…
Zhijian Jake Tu · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2024 · $738,552 — Abstract Sex is critical to the survival and evolution of sexually reproducing organisms including mosquitoes. A dominant male-determining factor (M factor) is the primary signal that controls sex-determination in mosquitoes. Nix, the M factor in the yellow fever mosquito Aedes aegypti, is the first…
Bing Chen · BOSTON CHILDREN'S HOSPITAL · 2024 · $784,041 — Summary Structural insights from our recent work provide a strong scientific premise for exploring the membrane-related components of HIV-1 envelope glycoprotein (Env), including the membrane proximal external region (MPER), the transmembrane domain (TMD) and the cytoplasmic tail (CT), for vaccine d…
Jasdave Chahal · TIBA BIOTECH, LLC · 2024 · $965,678 — Project Abstract Avian influenza A H7N9 causes severe respiratory illness with a high mortality rate, and its zoonotic capacity has raised serious concerns over the possibility of a pandemic. The value of vaccines for pandemic-potential viruses has been demonstrated by the devastating effects of COV…
Kenneth Ber Margulies · UNIVERSITY OF PENNSYLVANIA · 2024 · $793,828 — The delivery of therapeutic nucleotides to the myocardium is notoriously challenging and remains an important unmet clinical need. Based on the global success of mRNA vaccines, solid lipid nanoparticles are the most widely used vehicle for RNA delivery. We recently identified species of lipid nanopa…
Guizhi Zhu · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $542,272 — Small circular mRNA vaccines Abstract: Vaccines save numerous lives each year. Conventional vaccines based on pathogens, DNA, proteins, or peptides are associated with poor pharmacokinetics, limited biostability, preexisting anti-viral-vector immunity, weak immunogenicity, or safety concerns over ge…